Helicobacter pylori Treatment Strategies in Singapore

키워드

참고문헌 (41)

1. "Population Trends 2018" (2018)[URL]
2. "Census of population 2010" (2011)[URL]
3. Fock KM, "Helicobacter pylori infection : current status in Singapore", Ann Acad Med Singapore, 26, pp.637~641 (1997)
4. Ang TL, "Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population", J Gastroenterol Hepatol, 20, pp.1603~1609 (2005)
5. Fock KM, "Second Asia-Pacific consensus guidelines for Helicobacter pylori infection", J Gastroenterol Hepatol, 24, pp.1587~1600 (2009)
6. Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
7. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
8. Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
9. Mahachai V, "Helicobacter pylori management in ASEAN : the Bangkok consensus report", J Gastroenterol Hepatol, 33, pp.37~56 (2018)
10. Fallone CA, "The Toronto Consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
11. Fallone CA, "Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics", Gastroenterology, 157, pp.44~53 (2019)
12. Zhao B, "Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia : a metaanalysis of randomized controlled studies with 12-month follow-up", J Clin Gastroenterol, 48, pp.241~247 (2014)
13. Vergara M, "Meta-analysis : role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users", Aliment Pharmacol Ther, 21, pp.1411~1418 (2005)
14. Gisbert JP, "H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without longterm maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer", Cochrane Database Syst Rev, (2), pp.CD004062~ (2004)
15. Lee YC, "Association between Helicobacter pylori eradication and gastric cancer incidence : a systematic review and meta-analysis", Gastroenterology, 150, pp.1113~1124 (2016)
16. Sachs G, "Gastric infection by Helicobacter pylori", Curr Gastroenterol Rep, 13, pp.540~546 (2011)
17. Gisbert JP, "Meta-analysis : proton pump inhibitors vs. H2-receptor antagonists : their efficacy with antibiotics in Helicobacter pylori eradication", Aliment Pharmacol Ther, 18, pp.757~766 (2003)
18. Vallve M, "Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication : a meta-analysis", Aliment Pharmacol Ther, 16, pp.1149~1156 (2002)
19. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
20. Fischbach L, "Meta-analysis : the effect of antibiotic resistance status on the efficacy of triple and quadruple firstline therapies for Helicobacter pylori", Aliment Pharmacol Ther, 26, pp.343~357 (2007)
21. Yuan Y, "Optimum duration of regimens for Helicobacter pylori eradication", Cochrane Database Syst Rev, (12), pp.CD008337~ (2013)
22. Molina-Infante J, "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance", Gastroenterology, 145, pp.121~128 (2013)
23. Fock KM, "Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease : results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group", Aliment Pharmacol Ther, 14, pp.225~231 (2000)
24. Wong BC, "Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer : an Asian multicentre double-blind randomized placebo controlled study", Aliment Pharmacol Ther, 14, pp.217~224 (2000)
25. Ang TL, "Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis", J Dig Dis, 14, pp.100~104 (2013)
26. Gatta L, "Sequential therapy or triple therapy for Helicobacter pylori infection : systematic review and meta-analysis of randomized controlled trials in adults and children", Am J Gastroenterol, 104, pp.3069~3079 (2009)
27. Essa AS, "Meta-analysis : four-drug, three-antibiotic, non-bismuth-containing"concomitant therapy"versus triple therapy for Helicobacter pylori eradication", Helicobacter, 14, pp.109~118 (2009)
28. Ang TL, "Ten-day triple therapy versus sequential therapy versus concomitant therapy as firstline treatment for Helicobacter pylori infection", J Gastroenterol Hepatol, 30, pp.1134~1139 (2015)
29. Ang TL, "The changing profile of Helicobacter pylori antibiotic resistance in Singapore : a 15-year study", Helicobacter, 21, pp.261~265 (2016)
30. Chew CA, "The diagnosis and management of H. pylori infection in Singapore", Singapore Med J, 58, pp.234~240 (2017)
31. Ang TL, "Efficacy of quadruple therapy for Helicobacter pylori eradication after failure of proton pump inhibitor based triple therapy in Singapore", Chin J Dig Dis, 4, pp.35~39 (2003)
32. Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)
33. Nishizawa T, "Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing", Front Mol Biosci, 1, pp.19~ (2014)
34. Vécsei A, "Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children", Clin Gastroenterol Hepatol, 8, pp.309~312 (2010)
35. Breuer T, "Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?", Am J Gastroenterol, 94, pp.725~729 (1999)
36. Kwon YH, "Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients : a prospective single tertiary center study", Scand J Gastroenterol, 51, pp.270~276 (2016)
37. Dore MP, "Role of bismuth in improving Helicobacter pylori eradication with triple therapy", Gut, 65, pp.870~878 (2016)
38. Ko SW, "Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy : systemic review and meta-analysis", Helicobacter, 24, pp.e12565~ (2019)
39. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
40. Li M, "Systematic review with meta-analysis : vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycinresistant strains of Helicobacter pylori", Helicobacter, 23, pp.e12495~ (2018)
41. Tanabe H, "Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication", Ann Clin Microbiol Antimicrob, 17, pp.29~ (2018)

관련 논문AI추천